Skip to main content

Table 1 Clinical baseline characteristics of 201 patients in the training and test groups

From: Multimodal ultrasound radiomics model combined with clinical model for differentiating follicular thyroid adenoma from carcinoma

Feature name

Training group (n = 141)

Test group (n = 60)

p’

FTA (n = 45)

FTC (n = 96)

p value

FTA (n = 23)

FTC (n = 37)

p value

Age(mean ± SD)

48.69 ± 15.53

45.15 ± 12.10

0.142

48.52 ± 13.54

50.68 ± 12.50

0.532

0.080

 Mean diameter(mm, median ± IQR)

16.45 ± 14.78

18.68 ± 11.10

0.207

17.90 ± 7.30

18.60 ± 11.45

0.927

0.947

Gender

  

0.230

  

0.970

0.483

 Female

39 (86.67)

75 (78.12)

 

19 (82.61)

32 (86.49)

  

 Male

6 (13.33)

21 (21.88)

 

4 (17.39)

5 (13.51)

  

Taller than wide

  

0.992

  

1.000

0.637

 Absent

37 (82.2)

79(82.3)

 

20(87.0)

31(83.8)

  

 Present

8 (17.8)

17 (17.7)

 

3(13.0)

6 (16.2)

  

 Location

  

0.975

  

0.900

0.174

 Isthmus

3 (6.67)

6 (6.25)

 

1 (4.35)

1 (2.70)

  

 Left

19 (42.22)

39 (40.62)

 

12 (52.17)

21 (56.76)

  

 Right

23 (51.11)

51 (53.12)

 

10 (43.48)

15 (40.54)

  

 Echogenicity

  

< 0.001

  

0.103

0.939

Hyperechogenicity

2 (4.44)

2 (2.08)

 

1 (4.35)

0.000

  

Isoechogenicity

15 (33.33)

6 (6.25)

 

6 (26.09)

4 (10.81)

  

Hypoechogenicity

28 (62.22)

88 (91.67)

 

16 (69.57)

33 (89.19)

  

 Composition

  

< 0.001

  

0.435

0.985

Cystic and solid

14 (31.11)

7 (7.29)

 

5 (21.74)

4 (10.81)

  

 Solid

31 (68.89)

89 (92.71)

 

18 (78.26)

33 (89.19)

  

Nodule-in-nodule

  

0.451

  

1.000

0.200

 Absent

42 (93.33)

84 (87.50)

 

22 (95.65)

35 (94.59)

  

 Present

3 (6.67)

12 (12.50)

 

1 (4.35)

2 (5.41)

  

Trabecular formation

  

0.024

  

0.164

0.405

 Absent

35 (77.78)

56 (58.33)

 

16 (69.57)

19 (51.35)

  

 Present

10 (22.22)

40 (41.67)

 

7 (30.43)

18 (48.65)

  

 Margin

  

0.437

  

0.329

0.748

 Smooth

19 (42.22)

34 (35.42)

 

11 (47.83)

13 (35.14)

  

Unclear or Irregular

26 (57.78)

62 (64.58)

 

12 (52.17)

24 (64.86)

  

 Halo

  

0.318

  

0.062

0.174

 Absent

37 (82.22)

79 (82.29)

 

15 (65.22)

30 (81.08)

  

Uniform Thin Halo

3 (6.67)

2 (2.08)

 

5 (21.74)

1 (2.70)

  

 Uneven halo

5 (11.11)

15 (15.62)

 

3 (13.04)

6 (16.22)

  

Tumor Protrusion

  

0.432

  

0.133

0.222

 Absent

28 (62.22)

53 (55.21)

 

18 (78.26)

22 (59.46)

  

 Present

17 (37.78)

43 (44.79)

 

5 (21.74)

15 (40.54)

  

 Calcification

  

< 0.001

  

0.013

0.349

 Absent

28 (62.22)

25 (26.04)

 

17 (73.91)

13 (35.14)

  

Microcalcification

10 (22.22)

40 (41.67)

 

3 (13.04)

9 (24.32)

  

Macrocalcification

7 (15.56)

31 (32.29)

 

3 (13.04)

15 (40.54)

  

 Arrival time

  

0.001

  

0.232

0.824

 Earlier

8 (17.78)

18 (18.75)

 

3 (13.04)

6 (16.22)

  

 Synchronous

31 (68.89)

37 (38.54)

 

15 (65.22)

16 (43.24)

  

 later

6 (13.33)

41 (42.71)

 

5 (21.74)

15 (40.54)

  

Perfusion defect

  

0.009

  

0.224

0.976

 Absent

20 (44.44)

22 (22.92)

 

9 (39.13)

9 (24.32)

  

 Present

25 (55.56)

74 (77.08)

 

14 (60.87)

28 (75.68)

  

Peak Intensity

  

0.668

  

0.152

0.462

Hypoenhancement

4 (8.89)

6 (6.25)

 

3 (13.04)

3 (8.11)

  

Isoenhancement

25 (55.56)

49 (51.04)

 

13 (56.52)

13 (35.14)

  

Hyperenhancement

16 (35.56)

41 (42.71)

 

7 (30.43)

21 (56.76)

  

Ring enhancement

  

< 0.001

  

0.006

0.375

 Absent

28 (62.22)

72 (75.00)

 

15 (65.22)

31 (83.78)

  

 Complete

15 (33.33)

1(1.04)

 

7 (30.43)

1 (2.70)

  

 Incomplete

2 (4.44)

23 (23.96)

 

1 (4.35)

5 (13.51)

  

C-TIRADS

  

< 0.001

  

0.128

0.538

 3

31(68.89)

27(28.12)

 

12(52.17)

8(21.62)

  

 4a

6(13.33)

24(25.00)

 

6(26.09)

9(24.32)

  

 4b

4(8.89)

15(15.62)

 

3(13.04)

10(27.03)

  

 4c

2(4.44)

17(17.71)

 

1(4.35)

5(13.51)

  

 5

2(4.44)

13(13.54)

 

1(4.35)

5(13.51)

  
  1. Data are numbers of patients, and data in parentheses are percentages. SD, standard deviation; IQR, range interquartile; p’: p value for comparison between training and test groups; mm, millimeter; FTC = Follicular thyroid carcinoma; FTA = Follicular thyroid adenoma